CD8A and melanoma: Applying the subset analysis described in this study to the single-cell transcriptome profiles of CD8+ T cells from human melanoma and NSCLC, which are currently the two most prevalent cancer types treated by anti-PD-1 therapy in the clinic, we could identify TOX as the top candidate TF for both cancer types.